title: Tirofiban-induced acute profound thrombocytopenia after primary angioplasty.
abstract: Glycoprotein IIb/IIIa inhibitors are used in the acute coronary syndromes and percutaneous coronary intervention as antiplatelet agents. However, these agents induce thrombocytopenia in approximately 1% to 5% of patients, and may lead to bleeding complications. Abciximab is associated with higher incidence of thrombocytopenia than eptifibatide and tirofiban. We describe a case of acute profound thrombocytopenia due to on tirofiban treatment in a patient who underwent primary angioplasty.
authors: Department of Cardiology, Pamukkale University Medical Faculty, Denizli, Turkey. dursundursunoglu@yahoo.com
authors: Dursun
authors: D
authors: Dursunoglu
authors: Ozgür
authors: O
authors: Taskoylu
authors: Sükrü
authors: S
authors: Gür
authors: Ismail
authors: I
authors: Sari
mesh_terms: D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects; D015415:Biomarkers / Q000097:blood; D017707:Erythrocyte Transfusion; D005343:Fibrinolytic Agents / Q000009:adverse effects*; D006801:Humans; D056989:Inferior Wall Myocardial Infarction / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects*; D010976:Platelet Count; D017713:Platelet Transfusion; D012720:Severity of Illness Index; D013921:Thrombocytopenia / Q000097:blood / Q000139:chemically induced* / Q000175:diagnosis / Q000628:therapy; D000077466:Tirofiban; D016896:Treatment Outcome; D014443:Tyrosine / Q000009:adverse effects / Q000031:analogs & derivatives*
chemical_list: D015415:Biomarkers; D005343:Fibrinolytic Agents; D010975:Platelet Aggregation Inhibitors; D014443:Tyrosine; D000077466:Tirofiban